Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies

Status:
Completed

Trial end date:
2017-02-01

Target enrollment:

Participant gender:

Hsp90 is a chemical in the body that is involved int he promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90.

Phase 1

Esanex Inc.